The Week in Review: October 20 – October 27, 2017

Friday, October 27, 2017 News Recap: Patient and Caregiver input is requested by BC Pharmacare on AbbVie’s combo of glecaprevir and pibrentasvir (GP) for Genotypes 1-6. We need to hear your voice by November 8, 2017!  AbbVie’s “GP” combo is pan-genotypic (works for all genotypes). Liver Meeting 2017: I’m A HCV Patient – Show Me What I Need to Know! Why reinvent the wheel? The good folks over at HCV New Drugs have put together this great overview o...

Transgene‘s Hepatitis B Vaccine Does the Business at Phase I

The French biotech‘s hepatitis B vaccine has demonstrated good efficacy and safety, suggesting it could provide effective protection from the virus. Biotech veteran, Transgene, specializes in viral-based immunotherapies for cancers and infectious diseases. One of its targets, hepatitis B, is a potentially fatal liver infection caused by the hepatitis B virus (HBV). Today, it has announced that its vaccine candidate, TG1050, has demonstrated good efficacy